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ABSTRACT
An accumulating body of evidence suggests that the endocannabinoid system plays a signiﬁcant
role in pathophysiological processes and impacts disease severity. Here we investigate the possible
role of a cannabinoid receptor type 2 (CB2) functional variant in determining disease severity and
the potential pharmacological therapeutic effects of CB2 activation in viral respiratory infection. The
common missense variant (CAA/CGG; Q63R) of the gene-encoding CB2 receptor (CNR2) was
evaluated in 90 inpatient and 90 outpatient children with acute respiratory tract infection (ARTI).
The frequency distribution of respiratory syncytial virus (RSV)-the main cause of severe cases of
bronchiolitis and pneumonia in children-was studied in all collected samples. The mechanism
through which CB2 affects clinical outcomes in case of RSV infection was studied in Balb/c mice
model using AM630 as a CB2 antagonist. The potential therapeutic effect of CB2 activation during
RSV infection was studied using a selective agonist, JWH133. The CB2 Q63R variation was associated
with increased risk of hospitalization in children with ARTI. Children carrying the QQ genotype were
more prone to developing severe ARTI (OR D 3.275, 95% CI: 1.221–8.705; p D 0.019). Of all the
children enrolled in the study, 83 patients (46.1%) were found positive for RSV infection. The
associated risk of developing severe ARTI following RSV infection increased more than two-fold in
children carrying the Q allele (OR D 2.148, 95% CI: 1.092–4.224; p D 0.026). In mice, the blockade of
CB2 by AM630 during RSV infection enhanced the inﬂux of BAL cells and production of cytokines/
chemokines while exaggerating lung pathology. CB2 activation by JWH133 reduces the inﬂux of
BAL cells and production of cytokines/chemokines while alleviating lung pathology. Collectively,
CB2 is associated with RSV severity during infancy and may serve as a therapeutic target in RSV
infection through the alleviation of virus-associated immunopathology.
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Introduction
Acute respiratory tract infections (ARTI) are one of the
most important causes of morbidity and mortality in
children; they are estimated to be responsible for approx-
imately two million childhood deaths globally.1–3 The
most common etiological agents causing ARTI in chil-
dren are the respiratory viruses (about 80% of respiratory
infections). Among the commonly encountered respira-
tory viruses, respiratory syncytial virus (RSV) has a ten-
dency to cause severe respiratory tract manifestations,
primarily bronchiolitis and pneumonia, among infants
and young children. Bronchiolitis and pneumonia are
the most common lower respiratory tract infections in
children and the leading cause of hospital admission
under six months of age. About 60–80% of all children
hospitalized with bronchiolitis and pneumonia are
infected by RSV.4–7 RSV accounts for about 33.1 million
episodes of acute lower respiratory tract infections per
year in children younger than ﬁve years, with 3.2 million
cases leading to hospitalization and up to 118,200
deaths.8 It is important to note that there are links
between RSV-associated bronchiolitis and pneumonia
and later development of asthma and wheeze.9,10
RSV infection leads to inﬁltration of various immune
cell types; if the lung recruitment of immune cells is dys-
regulated, the balance of viral control versus tissue
CONTACT Vahid Salimi vsalimi@tums.ac.ir Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
© 2018 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
VIRULENCE
2018, VOL. 9, NO. 1, 217–230
https://doi.org/10.1080/21505594.2017.1389369
damage is lost, resulting in pathology and severe dis-
ease.11-13 Despite many efforts to develop an RSV vac-
cine, there is a lack of effective prophylactic and
therapeutic agents, even though research continues to
uncover the complex mechanisms underlying RSV
immunopathogenesis.14 Several factors have been linked
to the severity of RSV infection in children, including
virus-related factors such as viral types and genotypes
and host-related factors such as preterm birth, birth
defects, and genetic variations.15-18 Genetic analyses of
children show an association of different polymorphisms
in speciﬁc host genes with severe RSV infection.19
Cannabinoids refer to a group of diverse compo-
nents that include substances of the plant Cannabis
sativa, endocannabinoids, and synthetic ingredients.20
The biological effects of cannabinoids are mediated
through the activation of G-protein-coupled cannabi-
noid receptors including CB1 and CB2.21 The psycho-
active function of cannabinoids are mediated through
CB1 as it is abundantly expressed in the central ner-
vous system. High-level CB2 expressions by immune
cells and the inducible expressions of these receptors
in inﬂammatory condition suggest that the anti-
inﬂammatory and immunomodulatory action of can-
nabinoids are CB2-dependent.22 This provides a ratio-
nale for a novel immunoregulatory role for the
cannabinoid system as a target for drug discovery for
the treatment of multiple inﬂammatory disorders.21
Recent studies have suggested a role for CB2 gene
(CNR2) polymorphism in immunity-associated dis-
eases pathogenesis.23–25 The single nucleotide poly-
morphism (SNP) rs35761398 in CNR2, which encodes
the CB2 receptors, substitutes glutamine (Q) 63 with
arginine (R) and affects the response of CB2 to canna-
binoids. The receptor carrying R showed a reduced
immune modulation function when activated by
cannabinoids.26
Although the effects of the endocannabinoid system
on immunity have received considerable attention, their
impact on respiratory viral immunopathology are still
unclear. It may be beneﬁcial to explore the implication
of the cannabinoid system and the virus may to maintain
immune homeostasis in viral infections. In this regard,
we studied the possible role of the CB2 Q63R functional
variant in respiratory disease severity in children and the
frequency distribution of RSV infection in children. We
expanded our CB2 studies to an in vivo system in which
CB2 was blocked by the selective antagonist AM630 dur-
ing RSV infection. In addition, by using the CB2 selective
agonist JWH133, we further tested how CB2 activation
affects the clinical outcome of RSV infection. The results
reported here provide evidence that CB2 receptors play
an important role in RSV disease severity.
Results
Human studies
Clinical data
Between December 2015 and April 2016, we admitted
180 patients (90 inpatients and 90 outpatients) to the
Bahrami Children Hospital. The patients’ ages ranged
from one month to 22 months with median and mean
ages of three and 4.65 months respectively. The common
clinical symptoms were sneezing, runny nose, cough,
dyspnea, and fever. The details of demographic, age, gen-
der, month, and clinical data according to the history of
inpatients and outpatients are shown in Table 1. Of all
the children enrolled in the study, 83 patients (46.1%)
were found positive for RSV. The prevalence of RSV was
45/83 (54.2%) in inpatients and 38/83 (45.8%) in outpa-
tients. Males (57.8%) were more affected than females
among the RSV-positive patients. The highest rates of
RSV infection were detected during winter.
Genetic data
The genotype distribution and allele frequencies for the
CB2 Q63R polymorphism of inpatients and outpatients
with ARTI are shown in Table 2. The frequencies of CB2
Q63R polymorphisms were found in the Hardy–Wein-
berg equilibrium among all the patients (p D 0.97), inpa-
tients (p D 0.43), and outpatients (p D 0.23). We found a
signiﬁcant difference between genotypic and allelic dis-
tributions of the Q63R polymorphism between the inpa-
tients and outpatients. The R allele, a common allele of
rs35761398, showed a lower frequency for hospitalized
infants compared with controls (OR D 0.630, 95% CI:
0.408–0.0973; p D 0.037)-this mean that the common
allele reduced the risk of hospitalization. Interestingly, a
signiﬁcant overrepresentation of the QQ genotype and
the Q allele was observed in the hospitalized patients
compared with controls (OR D 3.275, 95% CI: 1.221–
8.705; p D 0.019 and OR D 1.586, 95% CI: 1.027–2.449;
p D 0.037 respectively). The relative odds ratio suggested
that the risk of hospitalization was more than three-fold
in children with the QQ genotype.
The same result was observed in RSV-positive inpatients
and outpatients. Our data indicated that the polymor-
phisms of the CNR2 gene (Q63R) also affected the clinical
course of RSV infection (Table 2). In RSV-infected chil-
dren, the R allele had a lower frequency for inpatients than
outpatients (OR D 0.465, 95% CI: 0.236–0.915; p D 0.026
respectively). Thus, the common allele is associated with a
reduced risk of hospitalization in RSV-positive patients.
Moreover, in case of RSV-infected patients, overrepresenta-
tion of the QQ genotype and of the Q allele was observed
in inpatients compared with outpatients (OR D 4.5, 95%
CI: 0.908–22.29; p D 0.065 and OR D 2.148, 95% CI:
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1.092–4.224; p D 0.026, respectively). The associated risk of
developing severe ARTI following RSV infection signiﬁ-
cantly increased more than two-fold in children carrying
the Q allele. We did not ﬁnd any association between CB2
Q63R variants and clinical features (Table 3).
Mouse studies
The CB2 expression during primary RSV infection
To examine the effect of RSV infection on the expression
of CB2 receptors, we measured the CB2 mRNA expression
in the bronchoalveolar lavage (BAL) and the mice lungs
ﬁve days after the viral challenge. Our results showed that
the CB2 expression was signiﬁcantly enhanced in the BAL
cells of mice following RSV infection compared with unin-
fected mice (p< 0.007). We found no signiﬁcant difference
in the amount of the CB2 expression between the lung cells
of infected and uninfected mice (Fig. 1).
CB2 blockade and activation during RSV infection
The experimental design and the time course of antag-
onist (AM630) and agonist (JWH133) treatments in
RSV-challenged mice are shown in Fig. 2. Primary
RSV infection elicits an inﬂammatory response com-
prising a mixed population of leukocytes that inﬁl-
trates the pulmonary airways. The level of cells
inﬁltration following RSV infection was signiﬁcantly
enhanced in the CB2 blockade via AM630 (p < 0.05)
(Fig. 3). The differential analysis of the leukocytes in
the BAL of mice showed that the CB2 blockade
enhanced all leukocyte subsets, although only the neu-
trophil count was statistically signiﬁcant (p < 0.05). In
contrast, the data showed that CB2 activation through
JWH133 signiﬁcantly abrogated the RSV-induced leu-
kocyte migration into the lungs ﬁve days after viral
challenge (p < 0.05). The differential analysis of the
leukocytes in the BAL of mice showed that CB2 activa-
tion following RSV infection signiﬁcantly diminished
Table 1. Demographic, gender, age, month, and clinical data according to inpatients and outpatients.
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Age (month)
Median 3 3 3 3 3 3
Mean 4.78 4.51 4.65 4.44 4.02 4.23
Sex
Male 52 (57.8) 48 (53.3) 100 (55.6) 25 (55.6) 23 (60.5) 48 (57.8)
Female 38 (42.2) 42 (46.6) 80 (44.4) 20 (44.4) 15 (39.5) 35 (42.2)
Total 90 (100) 90 (100) 180 (100) 45 (100) 38 (100) 83 (100)
Months
December 2015 3 (3.3) 1 (1.1) 4 (2.2) 3 (6.7) 1 (2.6) 4 (4.81)
January 2016 65 (72.2) 46 (51.1) 111 (61.7) 33 (73.3) 20 (52.7) 53 (63.86)
February 2016 5 (5.6) 42 (46.7) 47 (26.1) 3 (6.7) 17 (44.7) 20 (24.1)
March 2016 17 (18.9) 1 (1.1) 18 (10) 6 (13.3) 0 (0) 6 (7.23)
Total 90 (100) 90 (100) 180 (100) 45 (100) 38 (100) 83 (100)
Age groups
1–2 months 34 (37.8) 40 (44.4) 74 (41.1) 18 (40) 15 (39.5) 33 (39.8)
2–3 months 13 (14.4) 8 (8.9) 21 (11.7) 8 (17.8) 5 (13.2) 13 (15.7)
3–4 months 7 (7.8) 5 (5.6) 12 (6.7) 4 (8.9) 1 (2.6) 5 (6)
4–5 months 4 (4.4) 9 (10) 13 (7.2) 3 (6.7) 6 (15.8) 9 (10.8)
5–6 months 11 (12.2) 5 (5.6) 16 (8.9) 5 (11.1) 2 (5.3) 7 (8.4)
6–8 months 6 (6.7) 11 (12.2) 17 (9.4) 2 (4.4) 6 (15.8) 8 (9.6)
8–10 months 3 (3.3) 2 (2.2) 5 (2.8) 1 (2.2) 1 (2.6) 2 (2.4)
10–12 months 7 (7.8) 8 (8.9) 15 (8.3) 3 (6.7) 1 (2.6) 4 (4.8)
12–22 months 5 (5.6) 2 (2.2) 7 (3.9) 1 (2.2) 1 (2.6) 2 (2.4)
Total 90 (100) 90 (100) 180 (100) 45 (100) 38 (100) 83 (100)
Clinical data
Fever 43 (47.8) 23 (25.6) 66 (36.7) 24 (53.3) 11 (28.9) 35 (42.2)
Sore throat 5 (5.6) 7 (7.8) 12 (6.7) 4 (8.9) 4 (10.5) 8 (9.6)
Cough 83 (92.2) 88 (97.8) 171 (95) 42 (93.3) 38 (100) 80 (96.4)
Dyspnea 73 (81.1) 52 (57.8) 125 (69.4) 36 (80) 21 (55.3) 57 (68.7)
Runny nose 87 (96.7) 88 (97.8) 175 (97.2) 44 (9.8) 37 (97.4) 81 (97.6)
Nasal congestion 69 (76.7) 77 (85.6) 146 (1.1) 36 (80) 34 (89.5) 70 (84.3)
Restlessness 3 (3.3) 1 (1.1) 4 (2.2) 3 (6.7) 1 (2.6) 4 (4.8)
Sneezing 84 (93.3) 88 (97.8) 172 (95.6) 41 (91.1) 37 (97.4) 78 (94)
Hemoptysis 1 (1.1) 3 (3.3) 4 (2.2) 1 (2.2) 2 (5.3) 3 (3.6)
Vomiting 3 (3.3) 0 (0) 3 (1.7) 3 (6.7) 0 (0) 3 (3.6)
Chills 1 (1.1) 0 (0) 1 (0.6) 1 (2.2) 0 (0) 1 (1.2)
Anorexia 2 (2.2) 0 (0) 2 (1.1) 2 (4.4) 0 (0) 2 (2.4)
Pneumonia 53 (58.9) 58 (64.4) 111 (61.7) 29 (64.4) 22 (57.9) 51 (61.4)
Bronchiolitis 6 (6.7) 0 (0) 6 (3.3) 4 (8.9) 0 (0) 4 (4.8)
Suspected to RSV 32 (35.6) 28 (31.1) 60 (33.3) 17 (37.8) 14 (36.8) 31(37.3)
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neutrophils and monocytes counts (p < 0.006 and p <
0.05, respectively) (Fig. 3).
The secreted inﬂammatory and anti-inﬂammatory
mediators were measured as indicators of immune cell
function in response to RSV challenge. As compared
with control conditions, the CB2 blockade signiﬁcantly
induced IFN-g and MIP-1a production (p< 0.05) as
well as non-signiﬁcantly decreased anti-inﬂammatory
Table 2. Genotype and allele frequencies of CNR2 gene in patients with acute respiratory infection.
Inpatient Outpatient P-value OR (95% CI)
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All cases QQ 17 (73.9) 6 (26.1) 1
QR 40 (48.25) 43 (51.8) 0.033 3.045 (1.092–8.493)
RR 33 (44.6) 41 (54.4) 0.017 3.520 (1.247–9.934)
QQ 17 (73.9) 6 (26.1) 1
QRCRR 73 (46.5) 84 (53.5) 0.019 3.275 (1.221–8.705)
RR 33 (44.6) 41 (55.4) 1
QRCQQ 57 (53.8) 49 (46.2) 0.156 0.642 (0.381–1.256)
Q 74 (57.4) 55 (42.6) 1
R 106 (45.8) 125 (54.2) 0.037 1.586 (1.027–2.449)
R 106 (45.8) 125 (54.2) 1
Q 74 (57.4) 55 (42.6) 0.037 0.630 (0.408–0.0973)
RSV (C) cases QQ 9 (81.8) 2 (18.2) 1
QR 18 (56.2) 14 (43.8) 0.144 3.5 (0.649–18.852)
RR 18 (45) 22 (55) 0.043 5.5 (1.052–28.752)
QQ 9 (81.8) 2 (18.2) 1
QRCRR 36 (50) 36 (50) 0.065 4.5 (0.908–22.29)
RR 18 (45) 22 (55) 1
QRCQQ 27 (62.8) 16 (37.2) 0.106 0.48 (0.201–1.166)
Q 36 (66.6) 18 (33.4) 1
R 54 (48.2) 58 (51.8) 0.026 2.148 (1.092–4.224)
R 54 (48.2) 58 (51.8) 1
Q 36 (66.6) 18 (33.4) 0.026 0.465 (0.236–0.915)
Table 3. Demographic, gender, age, and clinical data according to CNR2 variants.
All cases RSV (C) cases
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Sex
Male 11 (11) 41 (41) 48 (48) 100 (100) 0.109 5 (10.4) 16 (33.3) 27 (56.3) 48 (100) 0.220
Female 12 (15) 42 (52.5) 26 (32.5) 80 (100) 6 (17.1) 16 (45.7) 13 (37.2) 35 (100)
Total 23 (12.7) 83 (46.1) 74 (41.2) 180 (100) 11(13.2) 32 (38.6) 40 (48.2) 83 (100)
Age groups
1–2 months 7 (9.45) 42 (56.75) 25 (33.8) 74 (100) 0.053 4 (12.1) 15 (45.4) 14 (42.5) 33 (100) 0.800
2–3 months 3 (14.3) 9 (42.85) 9 (42.85) 21 (100) 2 (15.4) 6 (46.1) 5 (38.5) 13 (100)
3–4 months 2 (16.6) 4 (33.3) 6 (50) 12 (100) 2 (40) 1 (20) 2 (40) 5 (100)
4–5 months 4 (30.76) 5 (38.46) 4 (30.76) 13 (100) 1 (11.1) 2 (22.2) 6 (66.6) 9 (100)
5–6 months 0 (0) 7 (43.7) 9 (56.3) 16 (100) 1 (14.3) 1 (14.3) 5 (71.4) 7 (100)
6–8 months 0 (0) 5 (29.5) 12 (70.5) 17 (100) 1 (33.3) 1 (33.3) 1 (33.3) 3 (100)
8–10 months 0 (0) 3 (60) 2 (40) 5 (100) 0 (0) 1 (50) 1 (50) 2 (100)
10–12 months 5 (33.3) 5 (33.3) 5 (33.3) 15 (100) 0 (0) 2 (50) 2 (50) 4 (100)
12–22 months 2 (28.57) 3 (42.86) 2 (28.57) 7 (100) 0 (0) 0 (0) 2 (100) 2 (100)
Total 23 (12.8) 83 (46.1) 74 (41.1) 180 (100) 11(13.2) 32 (38.6) 40 (48.2) 83 (100)
Clinical data
Fever 7 (10.6) 31 (45) 28 (42.4) 66 (100) 0.801 5 (14.3) 13 (37.1) 17 (48.6) 35 (100) 0.960
Sore throat 3 (25) 5 (41.7) 4 (33.3) 12 (100) 0.417 1 (12.5) 4 (50) 3 (37.5) 8 (100) 0.773
Cough 21 (12.3) 79 (46.2) 71 (41.5) 171 (100) 0.668 10(12.5) 31 (38.7) 39 (48.8) 80 (100) 0.574
Dyspnea 16 (12.8) 61 (48.8) 48 (38.4) 125 (100) 0.503 7 (12.3) 24 (42.1) 26 (45.6) 57 (100) 0.614
Runny nose 22 (12.6) 80 (45.7) 73 (41.7) 175 (100) 0.612 11(13.6) 30 (37) 40 (49.4) 81 (100) 0.195
Nasal congestion 19 (13) 63 (43.1) 64 (43.9) 146 (100) 0.235 9 (12.8) 26 (37.2) 35 (50) 70 (100) 0.746
Restlessness 1 (25) 1 (25) 2 (50) 4 (100) 0.621 1 (25) 1 (25) 2 (50) 4 (100) 0.726
Sneezing 22 (12.7) 77 (44.7) 73 (42.4) 172 (100) 0.204 11(14.2) 28 (35.8) 39 (50) 78 (100) 0.139
Hemoptysis 0 (0) 2 (50) 2 (50) 4 (100) 0.735 0 (0) 2 (66.6) 1 (33.3) 3 (100) 0.551
Vomiting 1 (33.3) 1 (33.3) 1 (33.3) 3 (100) 0.559 1 (33.3) 1 (33.3) 1 (33.3) 3 (100) 0.574
Anorexia 1 (50) 1 (50) 0 (0) 2 (100) 0.220 1 (50) 1 (50) 0 (0) 2 (100) 0.207
Pneumonia 17 (15.4) 54 (48.6) 40 (36) 111 (100) 0.159 8 (15.7) 19 (37.3) 24 (47) 51 (100) 0.710
Bronchiolitis 1 (16.6) 4 (66.6) 1 (16.6) 6 (100) 0.462 1 (25) 3 (75) 0 (0) 4 (100) 0.142
Suspected to RSV 6 (10) 24 (40) 30 (50) 60 (100) 0.223 4 (13.3) 11 (36.6) 15 (50) 30 (100) 0.963
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cytokine IL-10 levels following RSV infection. While
RSV infection signiﬁcantly induced IFN-g and MIP-1a
and decreased IL-10 production, CB2 activation dis-
played signiﬁcantly decreased concentrations of IFN-g
and MIP-1a and increased IL-10 concentrations in the
BAL of mice ﬁve days after the viral challenge (p < 0.05)
(Fig. 4).
In agreement with the inﬂux of BAL immune cells, the
CB2 blockade impacts the accumulation of immune cells
in the peribronchial and perivascular spaces of the lungs,
although the differences did not reach statistical signiﬁ-
cance. In contrast, CB2 activation signiﬁcantly decreased
the accumulation of immune cells in the peribronchial
and perivascular spaces of the lung following RSV infec-
tion (p < 0.05) (Fig. 5). In this experiment, we followed
weight loss to determine whether the CB2 blockade and
activation have any impact on disease severity. Weight
loss is the hallmark of disease severity during RSV infec-
tion in the mice model. Our results showed that while
the CB2 blockade is associated with weight loss after
RSV infection, CB2 activation restored weight loss after
RSV infection (Fig. 6A). Furthermore, our results did
not show that the CB2 blockade and activation impacted
viral replication (Fig. 6B).
In these experiments, no differences were found in
mice that received PBS—whether they were treated with
AM630 or JWH133 alone—i.e., antagonist and agonist
induced no effects in the absence of RSV infection.
Discussion
The detection of speciﬁc viral causes of infection provides
a useful starting point for understanding illnesses attribut-
able to ARTIs and will guide future research studies. Epi-
demiological studies on the prevalence of RSV infection
are essential for developing diagnostic methods, efﬁcient
drugs, and vaccine design.16 Studies from Middle Eastern
countries, such as Iran, are rare. The frequency distribu-
tion of RSV infection in our study was 46.1%. The RSV
positivity rate was higher among inpatient children. The
majority of RSV-positive children (75.6%) were between
one to six months are in line with previous observations.27
Indeed, RSV represents a substantial burden of ARTIs
particularly in very young children, leading to severe mor-
bidity and hospitalization.28 Even with a limited sample
size, this study still provides much-needed information on
the prevalence of RSV in children aged less than two years
in the largest city of Iran. Signiﬁcant peaks of RSV preva-
lence were detected in the winter. This ﬁnding underlined
the seasonal characteristics of RSV infections in our study
group—this was consistent with the age patterns and sea-
sonal RSV prevalence reported in other studies.29 Season-
ality of virus is an important factor to optimize the timing
for potential interventions against these diseases and early
treatment therapies. The present study primarily focuses
on RSV infection as the main cause of severe respiratory
tract manifestations in children, while the possibility of
other viral respiratory infections, such as rhinovirus, meta-
Figure 1. The Effect of RSV infection on CB2 receptors expression.
Relative expression of CB2 receptor was evaluated in BAL and
lung of mice, 5 day after primary RSV or mock infection, using
speciﬁc primers targeting the CB2 genes, and normalized to those
of the housekeeping gene (b-actin). Results represent the mean
§SEM of 6 animals for each group. (p < 0.007).
Figure 2. Experimental design. Time course of antagonist (A) and agonist treatment (B) and experimental assays (C) in RSV challenged
mice.
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penumovirus, parainﬂuenza virus, and boca virus, needs
further studies.
Our knowledge of RSV pathogenesis and disease sever-
ity has increased over the last few years. It is crucial to
understand how RSV interacts with its host to facilitate
the development of safe and effective therapeutic inter-
ventions.30,31 Genetic analyses are not only important in
showing the likelihood of risk development toward severe
infections, but also provide information that characterizes
the disease pathogenesis.32 We had previously shown that
genetic variations in the opioid system (OPRM1), which
acts like a cannabinoid system, is associated with RSV dis-
ease severity: Carriers of the G allele are less prone to
develop severe RSV infections than those carrying the A
allele.19 The CB2 variants have been shown to affect the
ability of the CB2 receptor differently to exert its func-
tion.26 The CB2 Q63R variant affects the response of CB2
to cannabinoid by differently modulating the endocanna-
binoid-induced immune hemostasis, and consequently,
results in a lack of balance for immune responses that
may turn out to be a possible risk for immunity-associ-
ated disorders.33 The rationale of our study is based on
the assessed association between the CB2 Q63R variant
and several immunity-associated disorders as well as on
the well-known anti-inﬂammatory and immunomodula-
tory effects of CB2 signaling.23–25
The data from our study, for the ﬁrst time, suggests
that those with the CB2-63 RR variant is less prone to
developing severe respiratory tract infections and those
with the CB2-63 QQ variant is associated with more
severe respiratory tract diseases and the risk of hospitali-
zation. Although the study does not consider all respira-
tory viruses, the same result was observed in RSV-
positive infants carrying the Q allele. An explanation for
the association between the CB2 Q63R variant and the
risk of disease severity and hospitalization in children
with acute respiratory tract infections may be that the
immune response with QQ variants were more inhibited
when activated by an endogenous cannabinoid—i.e. a
less aggressive immune response against the virus—
thereby allowing the virus to replicate and induce severe
infection. Sip et al. found that the CB2-mediated inhibi-
tion of lymphocyte proliferation deriving from QQ sub-
jects was normal, while the one derived from RR subjects
was reduced.33 Such data indicated that the CB2 Q63R
variant will be part of the disease severity caused by RSV,
but further clinical investigations for larger case studies
are needed to conﬁrm this.
Figure 3. The Effect of CB2 receptors on immune cells inﬂux following RSV infection. CB2 receptors were blockade via using AM630 or
activated through JWH133 daily and the total cell counts (A), number of lymphocytes (B), monocytes (C), and neutrophil (D) of BAL cells
were determined on day 5 after infection. Results represent the mean §SEM of 6 animals for each group. (p < 0.05, p < 0.006).
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In the animal study, we found that RSV infection
can affect the CB2 expression in BAL cells—this is in
line with its high-level expression by immune cells and
the inducible expression in inﬂammatory condition.22 In
this study, the CB2 blockade is associated with
enhanced immunopathology, such as immune cells
inﬂux and increased IFN-g and MIP-1a production,
along with RSV-induced lung pathology and weight
loss. The results of our study are in line with previous
reports on the role of cannabinoids in inﬂuenza infec-
tion outcomes.34,35 Buchweitz et al. and Karmaus et al.
have shown that cannabinoid receptors null mice
exhibit a signiﬁcantly enhanced inﬂammatory response
to inﬂuenza infection, thereby strongly suggesting an
endogenous role for cannabinoid receptors in immune
regulation.34,35 Taken together, the current study and
those reported by others suggest that the CB2 receptors,
as the primary signaling pathway for endocannabinoid
Figure 4. The Effect of CB2 receptors on cytokine/chemokine production following RSV infection. CB2 receptors were blockade via using
AM630 or activated through JWH133 daily and the IFN-g (A), MIP-1a (B) and IL-10 (C) production were determined in BAL supernatant
on day 5 after infection. Results represent the mean §SEM of 6 animals for each group. (p < 0.05).
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immune modulation, may play a crucial role in main-
taining immune homeostasis and controlling the magni-
tude of the immune response through negative
regulation. However, to replicate the RSV infection seen
in children with different disease severity in a better
way, various RSV challenge doses should be tested in
future studies.
Since the activation of CB2 triggers anti-inﬂammatory
action, targeting these receptors may be a novel and
effective approach for the treatment of RSV-associated
immunopathology.30 In the present work, CB2 activation
enhanced IL-10 production and reduced bronchoalveo-
lar cellular inﬂux and IFN-g and MIP-1a production.
These effects result in the control of RSV-induced lung
Figure 5. The effect of CB2 receptors on lung pathology following RSV infection. CB2 receptors were blockade via using AM630 or acti-
vated through JWH133 daily and the lung pathology were determined on day 5 after infection. (A) Representative slides of hematoxylin
and eosin-stained lungs were analyzed and scored on day 5 after infection. (B) Pathology scores percentage for each group are shown.
Results represent the mean §SEM of 6 animals for each group. (p < 0.05).
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pathology and weight loss. This observation was consis-
tent with the immunosuppressive effects of CB2 activa-
tion reported by others.36–41 Some studies previously
indicated that CB2 activation inhibits immune cells
recruitment by activating the MAPK pathway.37,38 Cor-
rea et al. have shown that JWH-133 induces a sustained
activation of ERK1/2 MAP kinase, thereby contributing
to the downregulation of inﬂammatory cytokines.38
According to Kurihara et al., CB2 activation plays a role
in regulating excessive inﬂammatory response by con-
trolling RhoA activation.42 Moreover, JWH-133 amelio-
rates chronic colitis by inducing apoptosis, reducing the
number of activated T cells, suppressing mast cells, NK
cells, and neutrophils at inﬂammation sites.43 One of the
main ﬁndings in the present study was that JWH133 sig-
niﬁcantly decreases neutrophils recruitment following
RSV infection. Neutrophils play an important role in the
immunopathogenesis of RSV infection.44 Our results are
in line with Krohn et al. and Andrade-Silva et al., who
reported that CB2 activation inhibits neutrophil
recruitment.45,46 Murikinati et al. detected that JWH133
administration inhibits neutrophil recruitment at the site
of inﬂammation by activating p38.37 Thus, our results
imply that CB2 activation may act as a novel immuno-
modulatory strategy to alleviate RSV-induced lung
pathology through the inhibition of immune cells. How-
ever, it is important to ensure that the JWH133 effects
are attenuated with AM630 in future studies.
In conclusion, given the breadth of cannabinoids-medi-
ated regulation of the immunity function and the compli-
cated immunopathology associated with RSV infection,
our results indicate that: (i) the CB2 Q63R variant is associ-
ated with the clinical course of acute respiratory viral infec-
tions (ii) experimental RSV-induced immunopathogenesis
can bemodulated in part by endocannabinoids, as observed
by blocking the CB2 signaling, and (iii) RSV-induced
immunopathogenesis can be modulated by CB2 activation
and may be a novel approach for the treatment of RSV
bronchiolitis in children. However, caution is required due
to beneﬁcial/harmful functions of endocannabinoid
Figure 6. The effect of CB2 receptors on mice weight loss and viral load following RSV infection. (A) The graph shows changes in body
weight 5 days after the primary RSV or mock infection. (B) CB2 receptors were blockade via using AM630 or activated through JWH133
daily and RSV copy number was determined by quantitative real-time polymerase chain reaction in BAL supernatant on day 5 after
infection. Results represent the mean §SEM of 6 animals for each group.
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systems. It is important to note that different phases/stage
of RSV infection and different age groups may require dif-
ferent treatment approaches.
Patients and methods
Patients
We recruited 180 Iranian children under two years of age
with clinically suspected acute respiratory viral infection,
including 90 hospitalized patients (severe ARTI) and 90
outpatients (mild ARTI) during the winter season of
2016 at Bahrami Children’s Hospital, Tehran, Iran.
According to the Bahrami Children’s Hospital protocol
used for treatment of severe ARTI; the hospitalization
criteria contain respiratory distress including tachypnea,
nasal ﬂaring, chest retractions, or grunting. The respira-
tory rate >60 for children less than 2 month, respiratory
rate >50 for children between 2 month to 1 year and
respiratory rate >40 for children between 1 to 3 years
old were considered for hospitalized patients. A clinical
questionnaire was used to collect data from all patients
including age, gender, and symptoms like bronchiolitis,
pneumonia, fever, sore throat, cough, dyspnea, runny
nose, nasal congestion, and sneezing. The current human
study was approved by science and bioethics committee
of Tehran University of Medical Sciences.
Genotype analysis
Genomic DNA was extracted from nasopharyngeal swab
samples using a DNA extraction kit following manufac-
turers’ instructions (Roche, Germany). All samples were
genotyped for the CNR2 rs35761398 variant, which
changes the second and third adenosine at codon 63
(CAA) to guanosine (CGG) leading to the missense vari-
ant Q63R in the ﬁrst intracellular signaling loop of the
encoded CB2 protein. The genotypes of Q63R variation
were determined by using a TaqMan assay with commer-
cial probes (Thermo Fisher, USA). Both PCR and post-
PCR allelic discrimination was performed on an ABI
PRISM 7900 system (Applied Biosystems, USA). Geno-
types of random samples (10% in each experimental
group) were conﬁrmed by direct PCR sequencing with 50-
ATGCTGGGTGACAGAGATAG-30 (F), and 50-AGT-
CACGCTGCCAATCTTCA-30 (R) primers. The reaction
conditions were as follows: 94C for 4 min followed by 30
cycles of 94C for 50 s, 55C for 45 s, and 72C for 50 s.
Virus detection
Viral RNA was extracted from nasopharyngeal swab sam-
ples using viral high pure nucleic acid extraction kit
following manufacturers’ instructions (Roche, Germany).
Extracted RNA was converted into cDNA using a high-
capacity cDNA Reverse Transcription kit (Applied Biosys-
tems, USA) according to the manufacturer’s instructions.
The presence of RSV genome (N gene) in all collected
samples was analyzed through conventional PCR with 50-
GGAACAAGTTGTTGAGGTTTATGAATATGC-30 (F),
and 50-TTCTGCTGTCAAGTCTAGTACACTGTAGT-30
(R) primers. The reaction conditions were as follows:
94C for 4 min followed by 40 cycles of 94C for 30 s,
55C for 30 s, and 72C for 1 min.
Animal experiment
Six to nine-week-old female Balb/c mice (n D 36, 6 mice/
group), weighing 15–18 g were obtained from the Insti-
tute Pasteur, Karaj, Iran. The animals were transferred
and maintained in their home cages one week before the
beginning of the experiments. Mice were maintained in
individual cages with food/water ad libitum and in a con-
trolled environment in the animal house of Tehran Uni-
versity of Medical Sciences. All animal experiments were
approved by the animal ethics committee of the Tehran
University of Medical Sciences.
Mice were randomly assigned into controls (PBS-PBS,
AM630-PBS, PBS-JWH133) and challenged (PBS-RSV,
AM630-RSV, RSV-JWH13) groups. In order to investi-
gate the role of CB2 receptors in the immunopathogenesis
of RSV infection, AM630 (Sigma, USA) was injected i.p.
twice a day at a dose of 2 mg/kg. One day after the ﬁrst
antagonist treatment, mice were anesthetized with keta-
mine/xylazine and intranasally challenged with RSV-A2
at 5 £ 106 pfu/50 ml/mice dose. To determine the poten-
tial therapeutic effects of CB2 receptors activation in the
course of RSV infection, JWH-133 (Tocris Cookson Ltd,
U.K.) was injected i.p. 24 hrs after viral challenge (5 £
106 pfu/50 ml/mice) twice a day at a dose of 5 mg/kg. The
antagonist and agonist injection were continued daily up
to 5 days after infection and mice were sacriﬁced at day 5,
the peak day of viral load and inﬂammatory cells inﬂux
into the airways, and BAL ﬂuid (BALF) and lungs were
obtained, and then CB2 receptors expression, airway
immune cells inﬂux, cytokine/chemokine secretion, lung
histopathology, and viral load were assayed.
Drugs were dissolved in dimethyl sulfoxide and
diluted in normal saline 0.9% before administration.
Virus stuck was propagated on HEp-2 cells and puriﬁca-
tion was performed using polyethylene glycol precipita-
tion as described previously by our group.19 The puriﬁed
virus was resuspended and administrated in phosphate-
buffered saline (PBS) and the control groups received a
similar volume of PBS.
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CB2 receptors expression
In order to determine the expression level of CB2 recep-
tors following RSV infection, total RNA was extracted
from BAL cells and homogenized left lung lobe using
RNX reagent (SinaClone, Iran), according to the manu-
facturer’s instructions. Extracted mRNA was converted
into cDNA using 1 mg total RNA in a 25 ml reaction vol-
ume with a high-capacity cDNA Reverse Transcription
kit (Applied Biosystems, USA) according to the manu-
facturer’s instructions. For CB2 gene expression, Real-
time RT-PCR was performed on an ABI PRISM 7900
sequence-detection system (Applied Biosystems, USA)
using the SYBRs Premix ExTapTM II (Takara, Japan).
The reaction conditions were as follows: 95C for 30 s,
followed by 40 cycles of 95C for 5 s, 57C for 30 s, and
60C for 30 s. Melting curve conditions were as follows:
95C for 15 s and 65C for 1 min. The relative level of
gene expression was determined by the comparative
threshold cycle method as described by the manufac-
turer. Level of CB2 gene expression was normalized to
those of the housekeeping gene (b-actin) using the
2¡DDCt method and expressed in the graphs as “relative
expression”. The following primer pairs were used: CB2:
50-GGTGGACTTGTTGCCCTAGT-30 (F), 50-
TAGAAGCCAGCCCAGTAGGT-30 (R), and b-actin:
50-GCTCTGGCTCCTAGCACCAT-30 (F), 50-GCCACC-
GATCCACACAGAGT-30 (R).
BAL ﬂuid cell analysis
BALF was obtained 5 days after infection as described
previously by our group.19 The total number of cells
present in the BALF was counted with the aid of a light
microscope in Neubauer chambers, and differential leu-
kocyte counts were performed on smears stained with
Giemsa dye.
Cytokine and chemokine assay
The secretion of IFN-g, MIP-1a and IL-10 were mea-
sured with ELISA kits (PeproTech, USA), according to
the instructions of the manufacturer. Concentrations of
cytokines in the samples were calculated by interpolation
from the standard curve. The threshold of sensitivity for
IFN-g, MIP-1a, and IL-10 were 16 pg/ml, 4 pg/ml, and
39 pg/ml, respectively.
Histological analysis
Five day after challenge, mice were sacriﬁced and their
lung was obtained, and histology slides were prepared as
described previously by our group.19 Prepared slides
were evaluated by light microscope and lung pathology,
peribronchial and perivascular inﬁltration in the lungs
were scored as described previously.47,48 The average of
the sum of each reading was compared among groups.
Viral load assay
Nucleic acid was prepared from supernatants of BALF
using viral high pure nucleic acid extraction kit following
manufacturers’ instructions (Roche, Germany). Real-
time RT-PCR was performed on an ABI PRISM 7900
sequence-detection system (Applied Biosystems, USA)
using TagMan PCR Master Mix (Primer Design, UK)
and results were expressed as copy number/ml as
described previously.19
Statistical analyses
To evaluate the signiﬁcance of differences in genotype
and allelic frequencies a chi-square test or Fisher’s test
was performed by using SPSS 23 software (IBM, Chi-
cago, IL). Ninety-ﬁve percent conﬁdence interval (95%
CI) and Odds ratio (OR) were calculated. The OR was
adjusted by age and sex in the logistic regression model.
A linear logistic regression was performed to analyze
clinical data with respect to the CB2 Q63R variant.
Graph preparation and statistical analyses in animal
study were performed using GraphPad Prism v6.0 for
Windows (GraphPad Software Inc., San Diego, CA,
USA). The mean §SEM is expressed in all graphs. The
normality of date was performed using Kolmogorov–
Smirnov test. Differences between two groups were car-
ried out using Student’s t test for unpaired data. In both
human and animal study, differences were considered
signiﬁcant for p values < 0.05.
Abbreviations
ARTI Acute respiratory tract infections
RSV Respiratory syncytial virus
SNP Single-nucleotide polymorphism
OR Odds ratio
CI Conﬁdence interval
BAL Bronchoalveolar lavage
IFN-g Interferon-gamma
MIP-1a Macrophage inﬂammatory protein 1-alpha
IL-10 Interleukine-10
BALF BAL ﬂuid
HEp-2 Epithelial type 2
PBS Phosphate buffer saline
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